Brigatinib is a targeted cancer therapy known as a tyrosine kinase inhibitor (TKI). It is primarily used to treat non-small cell lung cancer (NSCLC) that has specific genetic mutations. Brigatinib is marketed under the brand name ALUNBRIG and was approved by the FDA in April 2017.
